Arthritis is the most common nonintestinal complication for people with ulcerative colitis (UC). These tips can help stave it ...

Black, Hispanic and female patients with ulcerative colitis were significantly less likely to undergo colectomy compared with ...

The combination showed efficacy exceeding that of either monotherapy ...

A new therapy that combines two existing drugs shows promise for patients with inflammatory bowel disease who have exhausted ...

New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease ...

LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...

Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with UC, including those in Ontario and ...

Before Abby Bales, a physical therapist in New York City, had surgery for ulcerative colitis, she couldn’t make it through the day without taking a nap. Bales was more than tired. She was experiencing ...

For patients with Crohn disease and ulcerative colitis (UC), a fixed-dose co-antibody therapy JNJ-4804 is efficacious.

Use of NSAIDs is not associated with an increased risk for disease-related hospitalization in ulcerative colitis, although a small increase is observed in Crohn’s disease.

For too long you have suffered from inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Crohn’s disease.

A new fixed-dose co-antibody therapy appears to be effective for managing ulcerative colitis and Crohn disease.